Literature DB >> 12858475

Development of tuberculosis in a patient treated with infliximab who had received prophylactic therapy with isoniazid.

Jorge Parra Ruiz, Norberto Ortego Centeno, Enrique Raya Alvarez.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12858475

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  4 in total

Review 1.  Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.

Authors:  K L Hyrich; A J Silman; K D Watson; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2004-07-08       Impact factor: 19.103

2.  Development of active tuberculosis following initiation of infliximab despite appropriate prophylaxis.

Authors:  S Raychaudhuri; R Shmerling; J Ermann; S Helfgott
Journal:  Rheumatology (Oxford)       Date:  2007-03-15       Impact factor: 7.580

3.  Development of Disseminated Tuberculosis with Intestinal Involvement due to Adalimumab Administration Despite Latent Tuberculosis Treatment.

Authors:  Kozo Ikuta; Yumiko Ota; Shigenobu Kuroki; Yoshihide Matsumoto; Eri Senda; Saki Mukohara; Soshi Takahashi; Kazuya Monden; Akihisa Fukuda; Hiroshi Seno; Shunichi Kumagai; Seiji Shio
Journal:  Intern Med       Date:  2019-11-22       Impact factor: 1.271

4.  Incidence of Active Tuberculosis within One Year after Tumor Necrosis Factor Inhibitor Treatment according to Latent Tuberculosis Infection Status in Patients with Inflammatory Bowel Disease.

Authors:  Jieun Kang; Dae Hyun Jeong; Minkyu Han; Suk-Kyun Yang; Jeong-Sik Byeon; Byong Duk Ye; Sang Hyoung Park; Sung Wook Hwang; Tae Sun Shim; Kyung-Wook Jo
Journal:  J Korean Med Sci       Date:  2018-10-23       Impact factor: 2.153

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.